What Is a Good ApoB Level?

Why ApoB Matters More Than LDL Cholesterol

A standard lipid panel reports LDL cholesterol as a concentration of cholesterol mass. What actually drives plaque formation is the number of atherogenic particles crossing into the arterial wall, and ApoB is a direct count of those particles. Every LDL, VLDL, IDL, and lipoprotein(a) particle carries exactly one ApoB molecule, so a single ApoB measurement reflects total atherogenic particle burden in a way that LDL-C cannot.

An analysis pooling data across multiple statin trials reportedly found that on-treatment ApoB tracked with major cardiovascular events at least as closely as on-treatment LDL-C. The exact number of trials and participants behind that specific figure should be checked against the primary paper before it is republished elsewhere as a precise statistic; the broader direction of the finding, that ApoB is at least as predictive as LDL-C in statin-treated patients, is consistent with other cohort data cited below.

Discordance between the two markers is most clinically relevant in people with insulin resistance, metabolic syndrome, or elevated triglycerides. In these situations LDL-C can look "normal" while ApoB remains high, because each LDL particle is smaller and carries less cholesterol. A person with an LDL-C of 100 mg/dL can have a meaningfully different ApoB and particle count depending on their metabolic state. Only ApoB captures that difference directly.

The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias recommend ApoB as a secondary treatment target, particularly when triglycerides exceed 200 mg/dL or LDL-C is very low [2]. The 2021 Canadian Cardiovascular Society dyslipidemia guideline also gives ApoB a prominent role as a marker of atherogenic particle concentration [3].

What the Numbers Mean: ApoB Targets by Risk Category

For adults without established cardiovascular disease and fewer than two traditional risk factors, an ApoB below 90 mg/dL is generally considered acceptable. The target drops as cardiovascular risk rises.

The 2019 ESC/EAS framework stratifies ApoB targets by risk category [2]:

• Low risk: ApoB below 100 mg/dL
• Moderate risk: ApoB below 80 mg/dL
• High risk (for example, diabetes without organ damage, or moderate chronic kidney disease): ApoB below 65 mg/dL
• Very high risk (for example, a prior heart attack, stroke, or diabetes with organ damage): ApoB below 55 mg/dL

The 2018 AHA/ACC cholesterol guideline does not set a formal ApoB target, but names ApoB as a "risk-enhancing factor" that can help guide statin initiation in people whose 10-year risk is borderline [4]. Measured ApoB at or above 130 mg/dL is generally considered elevated regardless of risk category.

Cardiovascular disease remains a leading cause of death in the United States [5], and because ApoB reflects total atherogenic particle count rather than cholesterol mass, a meaningful share of adults with "normal" LDL-C will still have an ApoB above the low-risk threshold, particularly those with excess visceral fat or insulin resistance.

A Decision Framework for Your ApoB Number

The right response to an ApoB result depends on your risk category, how far above target you are, and what you are already doing about it. This is not a substitute for a clinician's judgment about your specific case, but it lays out the questions that actually change the next step.

Step 1: Find your risk category and target.

Step 2: Size the gap between your result and your target.

• Small gap (within about 10-15 mg/dL of target), low or moderate risk: A trial of diet, weight management, and activity for 8-12 weeks before adding medication is reasonable for many people, absent other reasons to treat sooner.
• Larger gap, or high/very high risk: Guidelines generally favor starting or intensifying a statin rather than waiting on lifestyle changes alone, since the gap and the baseline risk both argue for faster, more reliable ApoB reduction [2][4].
• Already on a statin and still above target: Adding ezetimibe is the standard next step before escalating further [4]. If ApoB remains above target on a statin plus ezetimibe, that is a reasonable point to discuss a PCSK9 inhibitor or inclisiran with your clinician, especially at high or very high risk.

Step 3: Watch for exceptions that change the plan.

• ApoB at or above roughly 160 mg/dL, or LDL-C at or above 190 mg/dL: This pattern, especially with a family history of early heart disease, raises concern for familial hypercholesterolemia and warrants a discussion about further evaluation rather than a standard lifestyle-first approach.
• Statin intolerance: Muscle symptoms on one statin do not rule out all statins. A different statin, a lower dose, or non-statin add-on therapy are standard next steps before abandoning treatment.
• Pregnancy or planning pregnancy: Statins are not used in pregnancy. This changes the treatment plan and should be discussed directly with your clinician.
• Very high triglycerides: ApoB becomes especially important here because LDL-C calculations can be unreliable at high triglyceride levels.

Step 4: Confirm the timeline.

Recheck ApoB 4-12 weeks after starting or changing therapy, not sooner, since it takes time for the medication effect to stabilize. Once at target, annual monitoring is reasonable for most people.

How ApoB and LDL-C Become Discordant

Discordance is the situation where ApoB and LDL-C send conflicting signals, and it happens often enough to matter. An analysis of the Framingham Offspring Study found that a substantial minority of participants had discordant ApoB and LDL-C values, and among that group, cardiovascular event rates tracked more closely with ApoB than with LDL-C [6].

Three common causes of discordance:

Insulin resistance and metabolic syndrome. Excess hepatic production of VLDL leads to triglyceride-rich, cholesterol-poor LDL particles. Particle count is high, but cholesterol per particle is low, so LDL-C can underestimate true risk.

Familial hypercholesterolemia. Large, cholesterol-rich LDL particles can inflate LDL-C relative to particle number, so LDL-C may look proportionally higher than ApoB, though both are typically elevated.

Low LDL-C on therapy. Someone on a moderate-intensity statin may reach an LDL-C of 70 mg/dL while ApoB remains above 80 mg/dL, which suggests residual particle-driven risk that the LDL-C number alone would miss. A large international case-control analysis (the INTERHEART lipid substudy, conducted across 52 countries) has been reported to find that the ApoB-to-ApoA1 ratio was among the strongest lipid predictors of heart attack studied.

When LDL-C and ApoB disagree, most current guidance favors trusting ApoB for risk stratification, a position reflected in Canadian and European lipid guidelines.

When an Elevated ApoB Points Toward Statin Therapy

The 2018 AHA/ACC guideline recommends statin therapy for four groups: people with established atherosclerotic cardiovascular disease, those with LDL-C at or above 190 mg/dL, adults aged 40-75 with diabetes, and adults aged 40-75 with a 10-year cardiovascular risk at or above 7.5% [4]. An elevated ApoB is named as a factor that can tip the decision toward treatment in people whose calculated risk falls in a borderline range, roughly 5-7.5% 10-year risk [4].

A large pooled analysis of dozens of statin trials involving roughly 170,000 participants has reported that lowering LDL-C reduces major vascular events in a dose-dependent way, with benefit extending across a wide age range. High-intensity statin regimens (for example, atorvastatin 40-80 mg or rosuvastatin 20-40 mg) typically produce the largest ApoB reductions, commonly in the range of 40-55%.

Serious muscle injury (rhabdomyolysis) on statin therapy is rare, though anyone on a statin should report unexplained or severe muscle pain to their clinician promptly rather than waiting for a scheduled visit.

How to Lower Your ApoB

Lowering ApoB means targeting either the production or the clearance of atherogenic lipoproteins. Options with the strongest trial evidence, in roughly descending order of effect size:

High-intensity statin therapy. Typically the first step, with ApoB reductions in the 40-55% range for the highest-intensity regimens.

PCSK9 inhibitors added to a statin. Evolocumab and alirocumab are FDA-approved add-on therapies. The FOURIER trial, which enrolled patients with established cardiovascular disease already on statin therapy, found that adding evolocumab produced a large additional reduction in atherogenic lipoproteins and a reduction in major cardiovascular events over a median follow-up of a little over two years [9].

Ezetimibe added to a statin. Blocks intestinal cholesterol absorption and is the standard next step when a statin alone is not enough [4].

Inclisiran. A twice-yearly injectable that lowers LDL-C and ApoB as monotherapy or on top of a statin. The ORION-11 trial found a large, sustained LDL-C reduction out to roughly 500 days of follow-up [11].

Bempedoic acid. An option for people who cannot tolerate statins. The CLEAR Outcomes trial, conducted in statin-intolerant patients, found meaningful reductions in both LDL-C and major cardiovascular events [10].

Dietary changes. A "portfolio" dietary pattern combining plant sterols, viscous fiber, soy protein, and nuts has been reported to meaningfully reduce ApoB in a small randomized trial. Mediterranean-style eating patterns are associated with smaller but still meaningful reductions.

Weight loss. Meaningful weight loss lowers ApoB, with larger effects in people who have metabolic syndrome, though the exact reduction per kilogram varies by individual and should not be treated as a fixed number.

For people using GLP-1 receptor agonists such as semaglutide or tirzepatide for weight management, there is an indirect ApoB benefit through improved insulin sensitivity and reduced visceral fat. The STEP 1 trial found that semaglutide 2.4 mg produced substantially greater weight loss than placebo over 68 weeks, and secondary analyses reported concurrent improvements in atherogenic lipoproteins [13].

When to Recheck ApoB After Starting Treatment

After starting or adjusting lipid-lowering therapy, recheck ApoB at 4-12 weeks. This gives the medication time to reach steady state and allows hepatic LDL receptor upregulation to stabilize.

If ApoB remains above goal after an adequate trial of a high-intensity statin, adding ezetimibe is the standard next step before considering a PCSK9 inhibitor or inclisiran. Once ApoB is at target, annual monitoring is reasonable for most people.

No fasting is required for ApoB measurement, which makes it more convenient than a full fasting lipid panel. Sniderman and colleagues, writing in a 2019 narrative review, argued that ApoB should be measured routinely in people being evaluated for metabolic risk and in anyone on lipid-lowering therapy, since it captures information LDL-C alone can miss [14]. Cost and insurance coverage for ApoB testing vary by plan and by ordering physician; check directly with your insurer or lab rather than relying on a general estimate.

People taking statins should also have baseline liver enzyme testing and should report unexplained muscle pain to their clinician rather than waiting for a routine follow-up.